MedTrace Logo

Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2

NCT02371070 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2016-07-01

No results posted yet for this study

Summary

The investigators study aims to test the correlation between the Hemochron Signature point-of-care testing (POCT) device (ITC, USA) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC; rivaroxaban, apixaban and dabigatran) and to determine the diagnostic accuracy of POCT to rule out or detect relevant levels of DOAC in real-life stroke patients.

Conditions

  • Anticoagulation With Direct Oral Anticoagulants

Sponsors & Collaborators

  • Heart and Diabetes Center North Rhine-Westphalia

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Sven Poli, Dr. · University Hospital Tuebingen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-11-30
Completion
2016-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02371070 on ClinicalTrials.gov